Drugs / Neulastim
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02768714 Comparator | Jan 2018 → Oct 2019 | breast cancer | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03381417 Comparator | Oct 2016 → Nov 2017 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neulastim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03381417 ↗ |
| Route | Subcutaneous | “A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)” NCT02768714 ↗ |